德国的养猪育种者想要限制生物技术专利的范围。
German pig breeders want to limit the scope of biotech patents.
生物技术产业组织（BIO）最近召开了一个会议，其中部分议程就不断变化的专利领域向律师们提供了培训。
The BIO recently held a convention which included sessions to coach lawyers on the shifting landscape for patents.
总的来说，值得授予专利的发明和发现是在制药和生物技术领域，在该领域每年都能推出价值可达数十亿美元，影响重大的新药。
By and large, the inventions and discoveries worth patenting are those in the pharmaceutical and biotech fields, where the pay-off for blockbuster drugs can amount to billions of dollars a year.
生物技术公司将基因——正是生命的本原——申请了专利，科学家们则担心这将危及基础性研究的开展。
Biotechnology companies patent genes, the very stuff of life, while scientists worry that this risks compromising basic research.
生物技术的专利可能伴随着若干G的计算机数据。
A biotech patent may be accompanied by gigabytes of computer data.
所以当IncyteGenomics，一个同样位于帕洛阿尔托的生物技术公司于1997年以9000万美元的价格收购Synteni时，Affymetrix马上作出以专利侵权起诉了Incyte公司。
When Incyte Genomics, then a bioinformatics company based in Palo Alto, California, acquired Synteni for $90m in 1997, Affymetrix immediately sued Incyte for patent infringement.
生物仿制制药是对生物技术制药进行的非专利仿制(尽管不是完全一致的复制)。
Biosimilars are generic impersonations (although not identical copies) of biotech drugs.
但是，如果专利就像在生物技术，遗传学和其它学科领域发生的那样，实际上阻碍了将各项发明组合与再组合，以产生新的产品和工艺，那又如何来评价它哪？
But what if patents actually discourage the combining and recombining of inventions to yield new products and processes-as has happened in biotechnology, genetics and other disciplines?
通讯，化学，生物技术及商业方法的专利撰写的差别。
Variations in the drafting of patent applications for telecommunications, chemical, biotech and business method patents.
养猪育种者担心如果专利权被确认的话，则他们将来可能就不得不给美国生物技术公司支付使用费。
The pig breeders fear they might have to pay royalties to a US biotech firm in future if the patent is upheld.
欧洲药物管理部门近来开创了一条允许非专利生物技术药物进入市场的通道。
European drug regulators recently created a pathway for generic versions of biotech drugs to come to market.
所以真正的问题是那些希望成为非专利生物技术药物生产者的公司需要做出努力来赢得当局者的允许。
So the real question is what would-be manufacturers of biogenerics will be required to do to win approval here.
生物技术企业声称生物技术药物的复杂性和不可预知性意味着非专利生物技术药物在获得许可之前应经过广泛的人体测试实验。
The biotech industry says the complexity and unpredictability of biologically derived drugs mean generics should be subject to extensive tests in humans before being approved.
使地球基因库摆脱专利局的控制和商业性利用的斗争将是生物技术时代的关键战役之一。
The battle to keep the earth's gene pool free from the patent office and free of commercial exploitation is going to become one of the critical struggles of the biotech age.
在生物技术领域的基因专利到个人人类基因组工程，他都是一个经验丰富之人。文特尔博士对生物能源感兴趣不是一天两天了。
Dr Venter, a veteran of biotechnological scraps ranging from gene patenting to the private human-genome project, has been interested in bioenergy for a long time.
另外，还对如何解决基因资源的保护问题、生物技术领域是否需要专利保护和怎样防止生物技术的滥用等问题，介绍了自己的体会和建议。
Otherwise, the author has also given own Suggestions about how to protect the genetic resource, does biotechnology need patent protection and how to avoid misuse of biotechnology.
欧洲药物管理部门近来开创了一条允许非专利生物技术药物进入市场的通道。
European drug regulators recently created a pathway for generic ersions of biotech drugs to come to market.
Vical公司致力于基于其DNA传递专利技术的生物技术药物的研发，目的是为了预防和治疗严重的威胁生命的疾病。
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.
Vical公司致力于基于其DNA传递专利技术的生物技术药物的研发，目的是为了预防和治疗严重的威胁生命的疾病。
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.
应用推荐